CRISPR Therapeutics AG
CRSP Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$49.01
KIRA · Stoqly’s AI analyst, in plain words
- CRISPR Therapeutics AG had $3.5M of revenue in fiscal 2025, down 90.6% on the year before. Over five years, revenue changed +37.3% a year on average.
- Its operating margin was −18,933.6%, down 17,683.3 pts: of every 100 in sales, about −18,934 is left after running the business.
- CRISPR Therapeutics AG lost $582M in fiscal 2025.
- Free cash flow was −$346M in fiscal 2025, −9,855.5% of revenue.
- CRISPR Therapeutics AG has $2.0B more cash than debt.
Market cap
$4.7B
P/E
—
Revenue
$3.5M
Net income
−$582M
Free cash flow
−$346M
Operating margin
−18,933.6%
CRISPR Therapeutics AG in 30 seconds · fiscal 2025
Are sales growing?
−90.6%
No. Sales fell 90.6% last year.
Does it make a profit?
−16,569.8%
No. It lost money last year.
Does profit turn into cash?
−9,855.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What CRISPR Therapeutics AG does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- CRISPR Therapeutics AG
- CIK
- 0001674416
CRISPR Therapeutics AG · CRSP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $915M | $1.2M | $371M | $37.3M | $3.5M |
| Revenue growth | 127,154.9% | −99.9% | 30,885.5% | −89.9% | −90.6% |
| Operating margin | 40.8% | −56,190.4% | −60.0% | −1,250.4% | −18,933.6% |
| Net income | $378M | −$650M | −$154M | −$366M | −$582M |
| Net margin | 41.3% | −54,271.7% | −41.4% | −981.5% | −16,569.8% |
| Diluted EPS | $4.70 | −$8.36 | −$1.94 | −$4.34 | −$6.47 |
| Cash | |||||
| Cash from operations | $539M | −$496M | −$260M | −$143M | −$345M |
| Capital expenditure | $81.7M | $37.2M | $9.5M | $1.9M | $0.9M |
| Free cash flow | $457M | −$533M | −$270M | −$145M | −$346M |
| FCF margin | 50.0% | −44,484.9% | −72.7% | −387.7% | −9,855.5% |
| Share count change | 21.9% | −3.3% | 1.9% | 6.5% | 6.6% |
| Debt and strength | |||||
| Cash and short-term investments | $2.4B | $1.8B | $1.7B | $1.9B | $2.0B |
| Debt incl. finance leases | — | — | — | — | $0.0M |
| Shareholders' equity | $2.4B | $1.9B | $1.9B | $1.9B | $1.9B |
| Current ratio | 20.2x | 15.3x | 17.5x | 22.1x | 13.3x |
| Returns and quality | |||||
| Return on equity | 18.6% | −30.4% | −8.2% | −19.2% | −30.2% |
| Return on tangible equity | 15.7% | −34.7% | −8.2% | −19.0% | −30.3% |
| Piotroski F-score | 6 | 2 | 3 | 2 | 1 |
| Altman Z'' | 13.3 | 7.2 | 8.9 | 8.6 | 6.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$17.9M
6 insiders
Of sales under plans
62%
$11.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CRISPR Therapeutics AG · CRSP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $49.01 a share, the company is worth $4.7B.
Source: SEC EDGAR XBRL filings (CIK 0001674416). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.